Oxalic Acid

Oxalic Acid

SCHEMBL1840973

CCN(CC)CC.CCN(CC)CC.O=C(O)C(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.41
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPT P10636 1/20 0.35
AGTR1 P30556 1/20 0.35
TDP1 Q9NUW8 3/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
EYA2 O00167 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL216302 1.00 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL27532528 1.00 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL28460363 0.97 FFAR3 (0.39) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL27615093 0.97 FFAR3 (0.39) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL19209492 0.91 ARG1 (0.35) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL19209502 0.91 ARG1 (0.35) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL378701 0.89 FFAR3 (0.44) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL60768 0.89 FFAR3 (0.44) FFAR3CHRM2CHRM4CHRM5CHRM1
Pyruvate SCHEMBL21145028 0.87 CHRM2 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Oxalic Acid SCHEMBL28576882 0.87 TDP1 (0.43) FFAR3CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025132334-A1 RESISTS USING PFAS FREE PAGS MERCK PATENT GMBH (DE) 2025-06-26 WO disclosed
WO-2025075046-A1 ANALYSIS METHOD 株式会社ダイセル 2025-04-10 WO disclosed
US-20200179254-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2020-06-11 US disclosed
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-08-08 US disclosed
EP-3518878-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION Henkel AG & Co. KGaA (DE) 2019-08-07 EP disclosed
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION HENKEL AG & CO. KGAA (DE) 2019-07-18 US disclosed
US-8425867-B2 Oxalate sorbents for mercury removal EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-04-23 US disclosed
US-20130045149-A1 OXALATE SORBENTS FOR MERCURY REMOVAL Empire Technology Developement LLC 2013-02-21 US disclosed
WO-2013025197-A1 OXALATE SORBENTS FOR MERCURY REMOVAL EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-02-21 WO disclosed
EP-1861364-B1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION C P PHARMACEUTICALS INTERNAT C V (US) 2011-05-11 EP disclosed
US-7128976-B2 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2006-10-31 US disclosed
US-20030091838-A1 Composition for film formation, method of film formation, and silica-based film JSR CORPORATION (JP) 2003-05-15 US disclosed
US-5647116-A Method for stripping non-superconductive AG-based sheath formed on a wire NATIONAL SCIENCE COUNCIL (TW) 1997-07-15 US disclosed
US-5103042-A METHOD FOR REDUCING UNSATURATION OF POLYETHERS THE DOW CHEMICAL COMPANY (US) 1992-04-07 US disclosed
EP-0458262-A2 Method for reducing unsaturation of polyethers THE DOW CHEMICAL COMPANY (US) 1991-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240129-A1 CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CUTA, S100A10 FFAR3 2270/4885CHRM2 1867/4885CHRM4 3102/4885
US-20190216703-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, SRRM2, IK FFAR3 1837/4885CHRM2 1254/4885CHRM4 2814/4885
US-20190216714-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CD44, PCNA FFAR3 3218/4885CHRM2 1393/4885CHRM4 2434/4885
US-20200179254-A1 IMPROVED CONDITIONING HAIR TREATMENT PRODUCT WITH WASHOUT PROTECTION KRT18, CUTA, DSG1 FFAR3 2914/4885CHRM2 1307/4885CHRM4 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.